Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Tanner, Rikki M ^a   Lynch, Amy I ^b   Brophy, Victoria H ^c   Eckfeldt, John H ^b   Davis, Barry R ^d   Ford, Charles E ^d   Boerwinkle, Eric ^e   Arnett, Donna K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; DOXAZOSIN; GELATINASE B; LISINOPRIL; MACROPHAGE ELASTASE; MMP12 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HOMOZYGOTE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; STROKE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 9; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 80051997271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023609     Document Type: Article

References (50)

1. Galis ZS, Khatri JJ, (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90: 251-262.
2. Hlatky MA, Ashley E, Quertermous T, Boothroyd DB, Ridker P, et al. (2007) Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J 154: 1043-1051.
3. Hutchinson KR, Stewart JA Jr, Lucchesi PA, (2009) Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol.
4. Zhou S, Feely J, Spiers JP, Mahmud A, (2007) Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens 21: 861-867.
5. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, et al. (1998) Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32: 368-372.
6. Liang J, Liu E, Yu Y, Kitajima S, Koike T, et al. (2006) Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 113: 1993-2001.
7. Yamada S, Wang KY, Tanimoto A, Fan J, Shimajiri S, et al. (2008) Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol 172: 1419-1429.
8. Zervoudaki A, Economou E, Pitsavos C, Vasiliadou K, Aggeli C, et al. (2004) The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and-9 in essential hypertension. Am J Hypertens 17: 273-276.
9. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, et al. (2003) Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 17: 119-124.
10. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, et al. (2006) Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 47: 117-122.
11. Jin Y, Han HC, Lindsey ML, (2007) ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J Mol Cell Cardiol 43: 664-666.
12. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, et al. (2002) Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88: 525-530.
13. Yamamoto D, Takai S, Miyazaki M, (2008) Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol 588: 277-279.
14. Liebetrau M, Burggraf D, Wunderlich N, Jager G, Linz W, et al. (2005) ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats. Neurosci Lett 376: 205-209.
15. Jormsjo S, Ye S, Moritz J, Walter DH, Dimmeler S, et al. (2000) Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 86: 998-1003.
16. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, et al. (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579-1585.
17. Su L, Zhou W, Asomaning K, Lin X, Wain JC, et al. (2006) Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 27: 1024-1029.
18. Joos L, He JQ, Shepherdson MB, Connett JE, Anthonisen NR, et al. (2002) The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 11: 569-576.
19. Han YJ, Kim HN, Yoon JK, Yi SY, Moon HS, et al. (2009) Haplotype analysis of the matrix metalloproteinase-9 gene associated with advanced-stage endometriosis. Fertil Steril 91: 2324-2330.
20. Hirose Y, Chiba K, Karasugi T, Nakajima M, Kawaguchi Y, et al. (2008) A functional polymorphism in THBS2 that affects alternative splicing and MMP binding is associated with lumbar-disc herniation. Am J Hum Genet 82: 1122-1129.
21. Natividad A, Cooke G, Holland MJ, Burton MJ, Joof HM, et al. (2006) A coding polymorphism in matrix metalloproteinase 9 reduces risk of scarring sequelae of ocular Chlamydia trachomatis infection. BMC Med Genet 7: 40.
22. Shin A, Cai Q, Shu XO, Gao YT, Zheng W, (2005) Genetic polymorphisms in the matrix metalloproteinase 12 gene (MMP12) and breast cancer risk and survival: the Shanghai Breast Cancer Study. Breast Cancer Res 7: R506-512.
23. Kure M, Pezzolesi MG, Poznik GD, Katavetin P, Skupien J, et al. (2011) Genetic variation in the matrix metalloproteinase genes and diabetic nephropathy in type 1 diabetes. Mol Genet Metab.
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama 288: 2981-2997.
25. Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group (2003) Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 42: 239-246.
26. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, et al. (2002) Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J 2: 309-317.
27. ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Jama 283: 1967-1975.
28. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, et al. (1996) Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 9: 342-360.
29. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, et al. (2008) Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. Jama 299: 296-307.
30. Burns JC, Shimizu C, Shike H, Newburger JW, Sundel RP, et al. (2005) Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun 6: 438-444.
31. Johnson JL, George SJ, Newby AC, Jackson CL, (2005) Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A 102: 15575-15580.
32. National Library of Medicine, US National Institutes of Health Chlorthalidone Tablet. Daily Med: Current Medication Information web site. Available: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acee7938-90a7-4d6a-a205-d4670a031d43. Accessed 2008 July 23.
33. DrugBank Chlorthalidone. DrugBank web site. Available: http://www.drugbank.ca/drugs/DB00310. Accessed 2009 July 31.
34. Seeland U, Kouchi I, Zolk O, Itter G, Linz W, et al. (2002) Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol 34: 151-163.
35. DrugBank Amlodipine. DrugBank web site. Available: http://www.drugbank.ca/drugs/DB00381. Accessed 2009 July 31.
36. Takai S, Yamamoto D, Jin D, Inagaki S, Yoshikawa K, et al. (2007) Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters. Eur J Pharmacol 568: 231-233.
37. Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, et al. (2007) Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 43: 670-676.
38. Yamamoto D, Takai S, Miyazaki M, (2007) Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem Biophys Res Commun 354: 981-984.
39. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, et al. (2004) Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation 109: 2143-2149.
40. Kerkela E, Bohling T, Herva R, Uria JA, Saarialho-Kere U, (2001) Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. Bone 29: 487-493.
41. Lavigne MC, Thakker P, Gunn J, Wong A, Miyashiro JS, et al. (2004) Human bronchial epithelial cells express and secrete MMP-12. Biochem Biophys Res Commun 324: 534-546.
42. Matsuno H, Ishisaki A, Nakajima K, Kozawa O, (2004) Effect of a synthetic matrix metalloproteinase inhibitor (ONO-4817) on neointima formation in hypercholesterolemic hamsters. J Cardiovasc Pharmacol 44: 57-65.
43. Jguirim-Souissi I, Jelassi A, Addad F, Hassine M, Najah M, et al. (2007) Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease. Am J Cardiol 100: 23-27.
44. Morgan AR, Rerkasem K, Gallagher PJ, Zhang B, Morris GE, et al. (2004) Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke 35: 1310-1315.
45. Canavesi M, Baldini N, Leonardi A, Sironi G, Bellosta S, et al. (2004) In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol 44: 416-422.
46. Armstrong C, Abilleira S, Sitzer M, Markus HS, Bevan S, (2007) Polymorphisms in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke 38: 2895-2899.
47. Bots ML, Hofman A, Grobbee DE, (1997) Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 28: 2442-2447.
48. Yasmin, McEniery CM, O'Shaughnessy KM, Harnett P, Arshad A, et al. (2006) Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 26: 1799-1805.
49. Ye S, (2006) Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69: 636-645.
50. Ye S, (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19: 623-629.